Volume 4,Issue 3
Objective: To investigate and analyze the safety and effectiveness of accelerated repetitive transcranial magnetic stimulation (arTMS) in the treatment of post-stroke depression. Methods: 70 patients with post-stroke depression from the Department of Psychiatry were selected as research subjects for this study. The study period was from June 2022 to June 2023. The patients were divided into the arTMS group and the general treatment group, with 35 cases in each group. The arTMS group received arTMS and the general treatment group received conventional treatment. The overall efficacy, related scores, sleep level, quality of life, and side effects of treatment were compared between the groups. Results: The overall efficacy of aRTMS was ideal. Besides, there were no significant differences in the scores of relevant scores between the two groups before treatment; after treatment, the arTMS demonstrated a greater decrease in the scores. Besides, the sleep quality of the patients in the arTMS group was better (P < 0.05). Furthermore, the quality of life of the arTMS group was significantly improved (P < 0.05). Lastly, arTMS treatment resulted in fewer adverse reactions, which indicated that it is safer compared to conventional treatment (P < 0.05). Conclusion: arTMS is more effective and secure in the treatment of post-stroke depression.